Last reviewed · How we verify

Cetuximab + FOLFIRI — Competitive Intelligence Brief

Cetuximab + FOLFIRI (Cetuximab + FOLFIRI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + chemotherapy combination. Area: Oncology.

phase 3 Monoclonal antibody + chemotherapy combination EGFR (cetuximab component); Topoisomerase I (irinotecan component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cetuximab + FOLFIRI (Cetuximab + FOLFIRI) — Cinnagen. Cetuximab blocks EGFR signaling while FOLFIRI chemotherapy damages DNA, together targeting colorectal cancer cells through dual mechanisms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cetuximab + FOLFIRI TARGET Cetuximab + FOLFIRI Cinnagen phase 3 Monoclonal antibody + chemotherapy combination EGFR (cetuximab component); Topoisomerase I (irinotecan component)
R-combination chemotherapy R-combination chemotherapy Shandong Provincial Hospital marketed Monoclonal antibody + chemotherapy combination CD20
Trastuzumab+ chemotherapy Trastuzumab+ chemotherapy Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. phase 3 Monoclonal antibody + chemotherapy combination HER2 (human epidermal growth factor receptor 2)
R-CHOP/R-DHAP R-CHOP/R-DHAP Prof. Dr. M. Dreyling (co-chairman) phase 3 Monoclonal antibody + chemotherapy combination CD20 (rituximab component)
R-pola-mini-CHP R-pola-mini-CHP Nordic Lymphoma Group phase 3 Monoclonal antibody + chemotherapy combination CD20
Bevacizumab + FOLFIRI-3 Bevacizumab + FOLFIRI-3 AryoGen Pharmed Co. phase 3 Monoclonal antibody + chemotherapy combination VEGF (bevacizumab); Thymidylate synthase and topoisomerase I (FOLFIRI-3)
Avastin®, paclitaxel, carboplatin Avastin®, paclitaxel, carboplatin Jiangsu HengRui Medicine Co., Ltd. phase 3 Anti-angiogenic monoclonal antibody + chemotherapy combination VEGF (bevacizumab); tubulin (paclitaxel); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + chemotherapy combination class)

  1. Fujian Medical University · 2 drugs in this class
  2. Shandong Provincial Hospital · 2 drugs in this class
  3. The Lymphoma Academic Research Organisation · 2 drugs in this class
  4. Fondazione Italiana Linfomi - ETS · 2 drugs in this class
  5. Nordic Lymphoma Group · 1 drug in this class
  6. Prof. Dr. M. Dreyling (co-chairman) · 1 drug in this class
  7. American Scitech International · 1 drug in this class
  8. Universität des Saarlandes · 1 drug in this class
  9. AryoGen Pharmed Co. · 1 drug in this class
  10. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cetuximab + FOLFIRI — Competitive Intelligence Brief. https://druglandscape.com/ci/cetuximab-folfiri. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: